Advances in New Technologies and Issues
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
One promising tool in the arsenal
to prevent HIV/AIDS is development of a vaccine. Extensive
research to find a safe and effective vaccine has been
ongoing for the last 15 years. International organizations,
including UNAIDS and WHO, the scientific community,
research agencies, the pharmaceutical industry, Governments
and communities are cooperating to intensify efforts
to develop a vaccine.
Vaccines have three potential roles
to play in combating HIV/AIDS. They could reduce susceptibility
to infection, reduce the rate of infection and/or disease
progression in vaccinated people who become infected,
and reduce the level of infectiousness of HIV- positive
persons.
Vaccine development is a complex
protracted process, involving biological research and
animal studies prior to conducting clinical trials on
human populations. This explains why, two decades after
the start of the pandemic, a suitable vaccine is still
not available.
To respond to the HIV pandemic,
there will be the need for multiple vaccines to be developed
to address the different subtypes of the virus. Global
surveillance is currently ongoing to assess the regional
variations in HIV subtypes.
Once the relevant vaccines have
been approved, several challenges are expected to arise
in implementing an HIV vaccine programme. Initially,
vaccines may not be fully effective. Because some studies
have indicated an increase in HIV risk-taking during
vaccine trials, intensive counselling will be required
to limit risk-taking behaviour.
Given the challenges ahead in developing
and then disseminating an HIV vaccine, it cannot, at
this stage in its development, be viewed as a panacea
but rather as a part of a comprehensive ongoing prevention
strategy.
<<
Back
Home Next >>
|